Stocktoria
Ocugen, Inc. OCGN
Ocugen, Inc. (OCGN) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $4.4M at a -1537.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OCGN | Ocugen, Inc. | 2/9 | — | — | — |
| CGON | CG Oncology, Inc. | 2/9 | — | — | — |
| CRSP | CRISPR Therapeutics AG | 1/9 | 6.42 | — | -90.6% |
| SRZN | Surrozen, Inc./DE | 2/9 | -15.54 | — | -67.4% |
| DBVT | DBV Technologies S.A. | 3/9 | -2.63 | — | — |
| DYAI | DYADIC INTERNATIONAL INC | 1/9 | — | — | — |
| ALGS | Aligos Therapeutics, Inc. | 2/9 | — | — | — |
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
FAQ
Is OCGN financially healthy?
Ocugen, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does OCGN pay a dividend?
No, Ocugen, Inc. does not currently pay a dividend.
How profitable is OCGN?
In FY2025, Ocugen, Inc. had a net margin of -1537.4%.
What is the analyst price target for OCGN?
The average Wall-Street price target for Ocugen, Inc. is $11.43, about 716.3% above the recent price, from 7 analysts.
Is OCGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Ocugen, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.